These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 33545022)

  • 1. A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States.
    Fitz-Patrick D; Young M; Scott DA; Scully IL; Baugher G; Peng Y; Jansen KU; Gruber W; Watson W
    Hum Vaccin Immunother; 2021 Jul; 17(7):2249-2256. PubMed ID: 33545022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age.
    Essink B; Peterson J; Yacisin K; Lal H; Mirza S; Xu X; Scully IL; Scott DA; Gruber WC; Jansen KU; Watson W
    Hum Vaccin Immunother; 2021 Aug; 17(8):2691-2699. PubMed ID: 33661716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age.
    Hurley D; Griffin C; Young M; Scott DA; Pride MW; Scully IL; Ginis J; Severs J; Jansen KU; Gruber WC; Watson W
    Clin Infect Dis; 2021 Oct; 73(7):e1489-e1497. PubMed ID: 32716500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States.
    Senders S; Klein NP; Lamberth E; Thompson A; Drozd J; Trammel J; Peng Y; Giardina PC; Jansen KU; Gruber WC; Scott DA; Watson W
    Pediatr Infect Dis J; 2021 Oct; 40(10):944-951. PubMed ID: 34525007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age.
    Klein NP; Peyrani P; Yacisin K; Caldwell N; Xu X; Scully IL; Scott DA; Jansen KU; Gruber WC; Watson W
    Vaccine; 2021 Sep; 39(38):5428-5435. PubMed ID: 34315611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan.
    Haranaka M; Young Song J; Huang KC; de Solom R; Yamaji M; McElwee K; Kline M; Aizawa M; Peng Y; Scully I; Kogawara O; Gruber WC; Scott DA; Watson W
    Vaccine; 2024 Feb; 42(5):1071-1077. PubMed ID: 38267330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults.
    Thompson A; Lamberth E; Severs J; Scully I; Tarabar S; Ginis J; Jansen KU; Gruber WC; Scott DA; Watson W
    Vaccine; 2019 Sep; 37(42):6201-6207. PubMed ID: 31495592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14™) administered to 6-8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III study.
    Matur RV; Thuluva S; Gunneri S; Yerroju V; Reddy Mogulla R; Thammireddy K; Paliwal P; Mahantshetty NS; Ravi MD; Prashanth S; Verma S; Narayan JP
    Vaccine; 2024 May; 42(13):3157-3165. PubMed ID: 38637211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination.
    Cannon K; Elder C; Young M; Scott DA; Scully IL; Baugher G; Peng Y; Jansen KU; Gruber WC; Watson W
    Vaccine; 2021 Dec; 39(51):7494-7502. PubMed ID: 34839993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years.
    Essink B; Sabharwal C; Cannon K; Frenck R; Lal H; Xu X; Sundaraiyer V; Peng Y; Moyer L; Pride MW; Scully IL; Jansen KU; Gruber WC; Scott DA; Watson W
    Clin Infect Dis; 2022 Aug; 75(3):390-398. PubMed ID: 34940806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial.
    Simon MW; Bataille R; Caldwell NS; Gessner BD; Jodar L; Lamberth E; Peng Y; Scott DA; Lei L; Giardina PC; Gruber WC; Jansen KU; Thompson A; Watson W
    Hum Vaccin Immunother; 2023 Aug; 19(2):2245727. PubMed ID: 37927075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase 3, Single-arm Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine in Healthy Children 15 Months Through <18 Years of Age.
    Meyer J; Silas P; Ouedraogo GL; McElwee K; Keep G; Trammel J; Peng Y; Scully IL; Gruber WC; Scott DA; Watson W
    Pediatr Infect Dis J; 2024 Jun; 43(6):574-581. PubMed ID: 38502894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase Three Study of the Safety and Immunogenicity of a Four-dose Series of 20-Valent Pneumococcal Conjugate Vaccine in Healthy Infants.
    Senders S; Klein NP; Tamimi N; Thompson A; Baugher G; Trammel J; Peng Y; Giardina P; Scully IL; Pride M; Center KJ; Gruber WC; Scott DA; Watson W
    Pediatr Infect Dis J; 2024 Jun; 43(6):596-603. PubMed ID: 38535409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability and immunogenicity of a novel 24-valent pneumococcal vaccine in toddlers: A phase 1 randomized controlled trial.
    Borys D; Rupp R; Smulders R; Chichili GR; Kovanda LL; Santos V; Malinoski F; Siber G; Malley R; Sebastian S
    Vaccine; 2024 Apr; 42(10):2560-2571. PubMed ID: 38360475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 3 Safety and Immunogenicity Study of a Three-dose Series of Twenty-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers.
    Korbal P; Wysocki J; Jackowska T; Kline M; Tamimi N; Drozd J; Lei L; Peng Y; Giardina PC; Gruber W; Scott D; Watson W
    Pediatr Infect Dis J; 2024 Jun; 43(6):587-595. PubMed ID: 38456705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Immunogenicity of V114, a 15-valent Pneumococcal Conjugate Vaccine, Compared with 13-valent Pneumococcal Conjugate Vaccine in Japanese Adults Aged ≥65 Years: Subgroup Analysis of a Randomized Phase III Trial (PNEU-AGE).
    Kishino H; Sawata M; Igarashi R; Shirakawa M; Pedley A; Musey L; Platt HL; Buchwald UK
    Jpn J Infect Dis; 2022 Nov; 75(6):575-582. PubMed ID: 35908869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.
    McFetridge R; Meulen AS; Folkerth SD; Hoekstra JA; Dallas M; Hoover PA; Marchese RD; Zacholski DM; Watson WJ; Stek JE; Hartzel JS; Musey LK
    Vaccine; 2015 Jun; 33(24):2793-9. PubMed ID: 25913828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).
    Platt HL; Cardona JF; Haranaka M; Schwartz HI; Narejos Perez S; Dowell A; Chang CJ; Dagan R; Tamms GM; Sterling T; Morgan L; Shi Y; Pedley A; Musey LK; Buchwald UK
    Vaccine; 2022 Jan; 40(1):162-172. PubMed ID: 34507861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED).
    Lupinacci R; Rupp R; Wittawatmongkol O; Jones J; Quinones J; Ulukol B; Dagan R; Richmond P; Stek JE; Romero L; Koseoglu S; Tamms G; McFetridge R; Li J; Cheon K; Musey L; Banniettis N; Bickham K;
    Vaccine; 2023 Jan; 41(5):1142-1152. PubMed ID: 36621410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE).
    Simon JK; Staerke NB; Hemming-Harlo M; Layle S; Dagan R; Shekar T; Pedley A; Jumes P; Tamms G; Sterling T; Musey L; Buchwald UK;
    Vaccine; 2022 Feb; 40(9):1342-1351. PubMed ID: 35039194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.